THE VISION
Paradigm shift in anastomotic technique
We innovate, manufacture and deliver
a new generation of surgical instruments
for colorectal surgery
HISTORY
2006
The start 2006
CarpoNovum is founded by two colorectal surgeons
Anders Grönberg, MD, PhD, engineer, and Prof. Henrik Thorlacius, MD, PhD
Award 2006
CarpoNovum received
Öhrlings Price Water House Coopers and LUIS Innovation awards
2007
Award 2007
CarpoNovum received the award for the most successful company in the Connect Sweden network
Award 2007
CarpoNovum received the national Skapa Development Award
2011
CE 2011
CARP®, predecessor of C-REX®, received CE marking
Developing 2011-2018
C-REX® device family was developed, clinical studies were conducted in Sweden, Denmark and China.
2018
CE 2018
CE mark is warded to the C-REX® portfolio
2020
Scandinavian CCS 2020
A subsidiary of CarpoNovum AB, is formed for surgical education and clinical practice.
ABOUT
CarpoNovum is a Swedish company innovating, manufacturing and delivering a new generation of surgical instruments for colorectal surgery.
Company’s headquarters, in-house R&D and manufacturing facilities are in Halmstad, Sweden.
Scandinavian Centre for Colorectal Surgery, a subsidiary of CarpoNovum, performs all clinical activities, including surgeons' training and accreditation.
BOARD OF DIRECTORS
Thomas Enckell, Attorney-at-law
Chairman of the Board
Thomas Enckell, chairman of the board, is a lawyer specialized in corporate and real estate law and transactions. He is a member of the Swedish Bar Association and has more than 20 years of experience in M&A and legal issues related to corporate governance. He acts as legal advisor to funds, private equity players and other private companies. Worked at several major Swedish law firms and is founder of Enckell Law Firm. Thomas is board member in a couple of companies in different business areas.
Jarl Jungnelius
Member of the Board
Trained as an MD and has previously held leading roles in oncology and clinical development at the pharmaceutical companies Celgene, Takeda, Pfizer, and Eli Lilly. Jarl Jungnelius is currently the CEO of Isofol Medical AB for a transitional period.
Ingrid Atteryd-Heiman
Member of the Board
Has been the head of 6 different companies and is currently Chairman of Ellen Asia Ltd. and Chairman at Doxa AB. Ms. Atteryd-Heiman received an MBA from the University of Uppsala and an undergraduate degree from the University of Lund.
Anders Grönberg
Member of the Board
Engineer, MD Ph.D., and Senior colorectal surgeon. Previously active in Halmstad and Malmö. Founder and CEO of CarpoNovum since 2006. Also, responsible for R&D applying his academic knowledge with a focus on wound healing on the intestine and the development of surgical instruments. Has conducted clinical studies since 2008 in Sweden, Denmark, Germany, and China.
Tommy Hedberg
Member of the Board
Senior Advisor in a number of life science companies. Tommy has extensive experience in international marketing and sales, clinical development, and product development in pharmaceuticals and medical technology companies such as Atos Medical, Medscand AB and Janssen Pharma AB. Tommy was the CEO of Atos Medical for 17 years.
Björn Zackrisson
Member of the Board
MD, Ph.D. former CEO for Skånegård Sund, which includes the hospitals in Ängelholm, Helsingborg, Landskrona, and Trelleborg with primary care in the corresponding area. Björn has been a member of the board of Niohundra AB in Norrtälje and Innovation Skåne and has held senior positions within Capio, Praktikertjänst, and Team Olivia.
Jonas Gulliksson
Member of the Board
Member of the Swedish and US Bar Associations, European Patent Attorney. Founder of the patent law firm Ström & Gulliksson and the law firm Advokatfirman Gulliksson. Former president of Licensing Executives Society International with extensive knowledge in business law, technology transfer agreements, and intellectual property prosecution. Jonas has almost 50 years of experience in national and international patent and intellectual property litigation and arbitration.
BOARD OF ADVISORS
Ludvig Arbin
Board of Advisors
Former county councilor in the region of Uppsala, responsible for public healthcare. In the past, Mr. Arbin was chancellor of the Swedish National Office for Cystic Fibrosis and has many years of experience as a consultant in the sphere of public decision-making in the Swedish healthcare system.
Roger Henriksson
Board of Advisors
Professor and senior oncologist at Norrland's University Hospital. Former leader of the regional Cancer Centrum Stockholm Gotland, and of Stockholms oncological clinic, including "Radiumhemmet" at Karolinska University Hospital. Furthermore, Mr. Henriksson has also been chairman of the expert panel advising Stockholm's medicinal committee.
Christophe Genetay
Board of Advisors
M.Sc. Civ Eng. and has 25 years experience in the financial industry, working with listed and non-listed companies. Former head of training at the Swedish Council for small investors. Since 2013 been engaged with Investor Relations across various industries.
Torbjörn Holm
Board of Advisors
M.D. and professor of surgery at Karolinska Institutet, with colorectal surgery as specialization. Has brought significant contributions to the development of the multi-disciplinary treatment of colorectal cancer in Sweden.
Magnus Jansson
Board of Advisors
Former CEO of Akademikliniken, which grew successfully through organic growth and acquisitions of hospitals and walk-in-clinics in Sweden, Denmark, and Norway. Today active as working chairman in a number of PE-owned companies.
Gunnar Németh
Board of Advisors
M.D. and professor of orthopedic surgery. Led the Karolinska hospital department for orthopedic surgery and acting subject specialist in Region Stockholm. He since worked with strategic development within Capio, before advancing to CEO for Capio S:t Görans hospital in 2007. Just over a year later, he took over as CEO of the Capio Group. And since 2011 he has been senior advisor across a number of companies.
Johan Stein
Board of Advisors
Lecturer and researcher at Stockholm School of Economics for 10 years. He gained a doctorate degree in 2011, later named docent and professor. Has been Head of research and portfolio manager at a number of hedge funds and with Nordea Investment Management. Also has experience from Alfred Berg and BNP Paribas.
Q&R
Quality and Regulatory
C-REX® devices are CE-marked in Europe. Regulatory approval has been achieved by complying with Medical Device Directive 93/42/EC as Class IIa devices and CarpoNovum holds a certificate of current version of EN ISO 13485.
Quality policy
All team members of CarpoNovum are committed to improve lives of people undergoing colorectal surgery, by providing high-quality, safe and effective products and services that meet our customers’ needs, with focus on continual improvement, by:
-
having a close collaboration with leading surgeons and health care professionals
-
complying with all applicable regulatory requirements
-
continually improving the effectiveness of our Quality Management System
-
periodically reviewing the performance of the Quality Management System and our Quality Objectives
-
communicating this Quality Policy to all team members, subcontractors and suppliers to assure that it is understood and implemented